Lilly’s Late-Stage CNS Pipeline Bare Following Edivoxetine Failure
This article was originally published in The Pink Sheet Daily
Depression candidate edivoxetine fails in three Phase III studies, marking a third recent blow to Lilly’s neuroscience pipeline efforts.
You may also be interested in...
Australia’s Prana Biotech Phase II Data On Huntington’s Candidate Holds Investor Interest With More To Come
Australia’s Prana Biotechnology has Phase II clinical trial data on a potential Huntington’s disease therapy to sustain a surge in the share price over the past year with more possibly on the way for an Alzheimer’s therapy.
Most of big pharma has crossed to the other side of the patent cliff and put their biggest losses behind them in 2012 and 2013, but a few major blockbusters will face new generic competition this year, including Nexium, Copaxone, and Nasonex.
FDA’s top new drug official called out industry’s innovation model, noting that major primary care markets are being left underserved as sponsors focus on precision medicine and rare diseases.